Evergreen Capital Management 13F: Adds $2.2M to LLY Stake

Evergreen Capital Management boosted its stake in Eli Lilly and Company LLY by 15.5% during the third quarter, according to a Form 13F filing with the SEC on October 23, 2026. The fund purchased an additional 1,878 shares, bringing its total ownership to 14,030 shares. The reported value of the holding reached approximately $16.2 million at the time of the filing.

LLY Eli Lilly and Company

$1,273.46 ▲ +18.44% year to date

1M 3M YTD

Daily close · Oct 23, 2026

What Changed in Evergreen Capital Management's Eli Lilly and Company Position

The fund increased its investment from 12,152 shares up to 14,030 shares. This 15.45% upward adjustment reflects a growing position in the major drug manufacturer as the company heads toward its next financial updates.

Other Institutional Activity in Eli Lilly and Company

Other institutional managers adjusted their positions around the October 23 filing date. AMF Tjanstepension grew its holdings by 65,262 shares, ending with 543,339 shares worth about $628.7 million. NTV Asset Management raised its Eli Lilly and Company stake by 2.0% to 31,222 shares valued at approximately $36.1 million. Conversely, Axxcess Wealth Management reduced its holdings by 12,282 shares, ending with 9,539 shares worth about $11.0 million. Wilmington Savings Fund Society, FSB trimmed its stake by 2,600 shares to finish with 25,292 shares valued at roughly $29.3 million. Ascent Wealth Partners bought 9,135 shares valued at approximately $10.6 million.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company closed at $1,273.46 on October 23, 2026, and recently traded around $1273.57 as of October 24, 2026. The stock trades above its 50-day moving average of $1,185.32 and its 200-day moving average of $1,084.11. Shares sit 3.6% below their 52-week high of $1,321.21 while resting well above their 52-week low of $806.02.

Recent Earnings

The drug manufacturer reported trailing twelve-month revenue of $79.7 billion alongside earnings of $29.79 per share. The company posted a net profit margin of 33.5% and a return on equity of 102.3%. Investors look ahead to the next earnings release scheduled for October 29, 2026.

Dividend

The company pays an annual dividend rate of $6.92 per share, giving it a dividend yield of 0.53% with a payout ratio of 21.7%.

Insider Buying and Selling at Eli Lilly and Company

Company insiders completed several transactions prior to the filing. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at an average price of $1,190.00 for a total value of $5.95 million. Officer Donald A Zakrowski parted with 2,000 shares on August 10, 2026, at an average price of $1,185.01 for a total value of $2.37 million. Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at an average price of $1,175.10 for a total value of $7.64 million.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock ahead of the filing. JP Morgan maintained an overweight rating on September 28, 2026, raising its target to $1,500.00 from $1,400.00. Morgan Stanley maintained an overweight rating on October 7, 2026, lifting its target from $1,419.00 to $1,430.00. Cantor Fitzgerald maintained an overweight rating on October 8, 2026, boosting its target to $1,440.00 from $1,410.00. RBC Capital reiterated an outperform rating with a $1,500.00 target on October 12, 2026. Leerink Partners maintained an outperform rating on October 21, 2026, raising its target to $1,316.00 from $1,309.00. Overall, the stock carries a consensus buy rating across 30 analyst opinions with a mean price target of $1,331.55.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products globally. The healthcare firm focuses on treatments for major conditions including diabetes, oncology, and immunology. Institutional interest remains strong as the company prepares its quarterly financial reports.

Bottom Line

Evergreen Capital Management expanded its exposure to Eli Lilly and Company during a period of steady market performance. Investors will monitor upcoming earnings results on October 29, 2026, for further financial updates. Future regulatory filings will reveal whether institutional accumulation continues through the end of the year.